Literature DB >> 9826622

Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.

O Roopnarine1, L A Leinwand.   

Abstract

We have studied the actin-activated ATPase activities of three mutations in the motor domain of the myosin heavy chain that cause familial hypertrophic cardiomyopathy. We placed these mutations in rodent alpha-cardiac myosin to establish the relevance of using rodent systems for studying the biochemical mechanisms of the human disease. We also wished to determine whether the biochemical defects in these mutant alleles correlate with the severity of the clinical phenotype of patients with these alleles. We expressed histidine-tagged rat cardiac myosin motor domains along with rat ventricular light chain 1 in mammalian COS cells. Those myosins studied were wild-type alpha-cardiac and three mutations in the alpha-cardiac myosin heavy chain head (Arg249Gln, Arg403Gln, and Val606Met). These mutations in human beta-cardiac myosin heavy chain have predominantly moderate, severe, and mild clinical phenotypes, respectively. The crystal structure of the skeletal myosin head shows that the Arg249Gln mutation is near the ATP-binding site and the Arg403Gln and Val606Met mutations are in the actin-binding region. Expressed histidine-tagged alpha-motor domains retain physiological ATPase properties similar to those derived from cardiac tissue. All three myosin mutants show defects in the ATPase activity, with the degree of enzymatic impairment of the mutant myosins correlated with the clinical phenotype of patients with the disease caused by the corresponding mutation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826622      PMCID: PMC1299973          DOI: 10.1016/S0006-3495(98)77743-4

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  48 in total

1.  A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.

Authors:  A A Geisterfer-Lowrance; S Kass; G Tanigawa; H P Vosberg; W McKenna; C E Seidman; J G Seidman
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

Review 2.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

3.  Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene.

Authors:  E Dausse; M Komajda; L Fetler; O Dubourg; C Dufour; L Carrier; C Wisnewsky; J Bercovici; C Hengstenberg; S al-Mahdawi
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

4.  Sarcomeric myosin heavy chain expressed in nonmuscle cells forms thick filaments in the presence of substoichiometric amounts of light chains.

Authors:  K L Vikstrom; A S Rovner; C G Saez; M Bravo-Zehnder; A J Straceski; L A Leinwand
Journal:  Cell Motil Cytoskeleton       Date:  1993

5.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

Authors:  H Watkins; A Rosenzweig; D S Hwang; T Levi; W McKenna; C E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

6.  Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation.

Authors:  N D Epstein; G M Cohn; F Cyran; L Fananapazir
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

7.  Functional analysis of myosin missense mutations in familial hypertrophic cardiomyopathy.

Authors:  A J Straceski; A Geisterfer-Lowrance; C E Seidman; J G Seidman; L A Leinwand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations.

Authors:  L Fananapazir; N D Epstein
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

9.  A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12.

Authors:  S D Solomon; A A Geisterfer-Lowrance; H P Vosberg; G Hiller; J A Jarcho; C C Morton; W O McBride; A L Mitchell; A E Bale; W J McKenna
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

10.  Identification of sequences necessary for the association of cardiac myosin subunits.

Authors:  E M McNally; M M Bravo-Zehnder; L A Leinwand
Journal:  J Cell Biol       Date:  1991-05       Impact factor: 10.539

View more
  19 in total

1.  Heterologous expression of wild-type and mutant beta-cardiac myosin changes the contractile kinetics of cultured mouse myotubes.

Authors:  Gaynor Miller; Joanne Maycock; Ed White; Michelle Peckham; Sarah Calaghan
Journal:  J Physiol       Date:  2003-02-07       Impact factor: 5.182

Review 2.  Mechanical and energetic consequences of HCM-causing mutations.

Authors:  Cecilia Ferrantini; Alexandra Belus; Nicoletta Piroddi; Beatrice Scellini; Chiara Tesi; Corrado Poggesi
Journal:  J Cardiovasc Transl Res       Date:  2009-10-09       Impact factor: 4.132

3.  The actin-myosin interface.

Authors:  Michael Lorenz; Kenneth C Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-24       Impact factor: 11.205

Review 4.  Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes.

Authors:  Jil C Tardiff
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

5.  Cell-intrinsic functional effects of the α-cardiac myosin Arg-403-Gln mutation in familial hypertrophic cardiomyopathy.

Authors:  Peiying Chuan; Sivaraj Sivaramakrishnan; Euan A Ashley; James A Spudich
Journal:  Biophys J       Date:  2012-06-19       Impact factor: 4.033

6.  Structural basis for myopathic defects engendered by alterations in the myosin rod.

Authors:  Anthony Cammarato; Xiaochuan Edward Li; Mary C Reedy; Chi F Lee; William Lehman; Sanford I Bernstein
Journal:  J Mol Biol       Date:  2011-10-20       Impact factor: 5.469

Review 7.  Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.

Authors:  A J Marian; L Salek; S Lutucuta
Journal:  Minerva Med       Date:  2001-12       Impact factor: 4.806

8.  Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy.

Authors:  J C Tardiff; T E Hewett; B M Palmer; C Olsson; S M Factor; R L Moore; J Robbins; L A Leinwand
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

9.  R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level.

Authors:  K A Palmiter; M J Tyska; J R Haeberle; N R Alpert; L Fananapazir; D M Warshaw
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

10.  Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone.

Authors:  Susan Lowey; Leanne M Lesko; Arthur S Rovner; Alex R Hodges; Sheryl L White; Robert B Low; Mercedes Rincon; James Gulick; Jeffrey Robbins
Journal:  J Biol Chem       Date:  2008-05-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.